Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective

De Mello, Ramon AndradeAyoub, EmiliCastelo-Branco, PedroDe Almeida Zia, Victor AndreSavio, AndrePozza, Daniel HumbertoTadokoro, HakaruTeich, Nelson2021-06-242021-06-242020-020732-183Xhttp://hdl.handle.net/10400.1/16569engOncologyComparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspectiveconference object